Ann Arbor, MI – According to filings with the U.S. Securities and Exchange Commission, HistoSonics is raising $33,505,278.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Mike Blue played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About HistoSonics

HistoSonics is a venture-backed medical device start-up company developing a non-invasive robotic platform and novel beam therapy, Robotically Assisted Sonic Therapy (RAST). RAST uses the science of histotripsy and the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform deliverers personalized, tissue specific treatments with unparalleled precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.

To learn more about HistoSonics, visit http://www.histosonics.com/

Contact:
Mike Blue, President and Chief Executive Officer
612-351-0361
mike.blue@histosonics.com
https://www.linkedin.com/in/mike-blue-860b9522/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved